Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
3(50.0%)
Early Phase 1
3(50.0%)
6Total
N/A(3)
Early Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT04355910Not ApplicableUnknown

Intermittent Fasting in Nonalcoholic Fatty Liver Disease

Role: lead

NCT02760511Not ApplicableCompleted

Anthocyanin Dose-escalation Study in Healthy Young Adults

Role: lead

NCT02317211Early Phase 1Completed

Purified Anthocyanins Supplementation in Type 2 Diabetes Mellitus

Role: collaborator

NCT01940263Early Phase 1Completed

Purified Anthocyanin and Nonalcoholic Fatty Liver Disease

Role: lead

NCT01940302Early Phase 1Completed

Dietary Supplement of LEHEL for the Patients With Type 2 Diabetes

Role: lead

NCT01707914Not ApplicableCompleted

Clinical Investigation on the Effects of Bayberry Juice Treatment in Adult Subjects With Features of Fatty Liver Disease

Role: lead

All 6 trials loaded